Pathophysiology

Type 1 RTA results from the failure of the alpha-intercalated (α-intercalated) cells of the collecting duct to secrete hydrogen ions into the tubular lumen, preventing appropriate urine acidification despite systemic acidosis. The collecting duct is normally responsible for fine-tuning acid-base balance, lowering urine pH to as low as 4.5. In dRTA, urine pH remains inappropriately alkaline (> 5.5) even when serum pH and HCO3 are significantly reduced.

Three distinct pathophysiologic mechanisms can cause dRTA, and understanding these helps predict clinical presentations:

1. Secretory (H+-ATPase) Defect — The most common mechanism. The H+-ATPase pump in the apical membrane of α-intercalated cells is dysfunctional or downregulated, preventing active H+ secretion. Genetic mutations (ATP6V1B1, ATP6V0A4) or acquired disease (Sjögren, amphotericin B toxicity) damage the pump itself.

2. Gradient (Back-Leak) Defect — Even if H+ is secreted, it leaks back across an abnormally permeable collecting duct epithelium, negating the pH gradient. This occurs in some genetic forms and with certain drugs.

3. Voltage (Lumen-Negative) Defect — H+ secretion is electrochemical and depends on a lumen-negative transepithelial voltage. Mutations affecting claudins or other tight junction proteins (SLC4A1 mutations affecting anion exchanger 1) can abolish this voltage gradient, preventing H+ secretion despite functional pumps.

The result is always the same: inability to lower urine pH below ~5.5 in the face of systemic acidosis. This is the defining diagnostic feature of Type 1 RTA.

The low urine citrate occurs because citrate is a weak acid that is freely filtered and then reabsorbed in the proximal tubule. In acidosis, citrate reabsorption is enhanced (to prevent urinary base loss), and citrate is also consumed in the buffering of the acidic environment. The result is severe citrate depletion, which removes a key inhibitor of calcium oxalate crystallization, predisposing to nephrolithiasis and nephrocalcinosis.

Etiologies of Type 1 RTA

Autoimmune Disorders — The most common cause of acquired dRTA in adult populations: - Sjögren syndrome (#1 autoimmune cause) — autoantibodies against H+-ATPase subunits and carbonic anhydrase II; dRTA occurs in up to 30% of Sjögren patients, though clinically manifest acidosis is rarer - Systemic lupus erythematosus (SLE) — tubulointerstitial nephritis with acid-secretion defect - Rheumatoid arthritis — associated with interstitial renal disease and dRTA - Primary biliary cholangitis (PBC) — autoimmune liver disease with cross-reactive renal involvement - Autoimmune hepatitis - Graves disease and other thyroiditis

Genetic/Hereditary Forms — Usually present in childhood or with family history: - ATP6V1B1 mutations (autosomal recessive) — encodes the B1 subunit of H+-ATPase; classically presents with dRTA + sensorineural hearing loss (deaf-RTA syndrome), often detected by newborn hearing screening - ATP6V0A4 mutations (autosomal recessive) — encodes the a4 subunit; another genetic pump mutation - SLC4A1 mutations (autosomal dominant or recessive) — encodes AE1 (anion exchanger 1, band 3 protein); can present as dominant dRTA or as part of hereditary spherocytosis - Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) — AIRE gene mutations; dRTA as part of multi-organ autoimmunity - Medullary sponge kidney (MSK) — congenital malformation with tubular dilations; presents with dRTA and nephrolithiasis/nephrocalcinosis

Medications — Drug-induced dRTA is important to recognize and potentially reversible: - Amphotericin B (classic — mechanism: creates pores in collecting duct epithelium allowing H+ back-leak and increased K+ wasting; both dRTA and hypokalemia develop during treatment; sometimes reversible if caught early) - Lithium (chronic use → collecting duct damage; also causes diabetes insipidus) - Ifosfamide (alkylating chemotherapy agent; cumulative toxicity) - Toluene (organic solvent, “glue sniffing”) — interesting pattern: initially presents as high-AG metabolic acidosis (hippuric acid), then converts to NAGMA/RTA as hippurate is excreted - NSAIDs (chronic use; less reliable than other causes)

Nephrocalcinosis Disorders — Calcification within kidney medulla leads to tubular damage: - Medullary sponge kidney (genetic) - Primary hyperparathyroidism (hypercalcemia, high urine calcium precipitate) - Vitamin D intoxication (granulomatous disease, excess supplementation) - Hypervitaminosis A (rare, chronic)

Tubulointerstitial Disease — Chronic inflammation/fibrosis damages the acid-secreting epithelium: - Chronic pyelonephritis or reflux nephropathy - Obstructive uropathy (if prolonged) - Renal allograft rejection (post-transplant dRTA) - Sickle cell disease (medullary infarction → tubulointerstitial scarring) - Chronic interstitial nephritis from any cause

Other Systemic Diseases: - Cirrhosis (reduced ammonia excretion, altered renal hemodynamics) - Wilson disease (copper deposition in collecting duct; also may cause Type 2 Fanconi features) - Ehlers-Danlos syndrome (connective tissue disorder affecting renal epithelium)

Clinical Features and Presentation

Hypokalemia — Often prominent (K+ typically 2.5-3.5 mEq/L). The mechanism is counterintuitive: because H+ secretion is blocked, the collecting duct’s response is to increase K+ secretion via principal cells as an alternative cation to “balance” the lack of H+. This potassium wasting leads to severe hypokalemia that can cause muscle weakness, cardiac arrhythmias, and rhabdomyolysis.

Nephrocalcinosis and Nephrolithiasis — The most distinctive complication. Up to 75% of dRTA patients develop kidney stones (usually calcium phosphate, which precipitates in alkaline urine) or medullary nephrocalcinosis (calcium deposits within the medulla, visible on ultrasound or CT). The mechanism involves: (1) high urine pH (alkaline urine favors calcium phosphate precipitation), (2) low urine citrate (loss of a key stone inhibitor), and (3) high urine calcium (from hypercalciuria if hypercalcemia present, or from chronic bone buffering).

Growth Retardation in Children — Chronic acidosis impairs linear growth through multiple mechanisms: (1) increased protein catabolism, (2) decreased growth hormone sensitivity, (3) bone disease from chronic buffering.

Bone Disease — Chronic metabolic acidosis is buffered in part by bone (osteoclast activation, mineral mobilization), leading to osteomalacia and osteoporosis. Children develop rickets (impaired mineralization) and adults develop accelerated bone loss.

Symptoms — Depend on severity and acuity. Mild asymptomatic dRTA may be found on lab screening. Severe or acute dRTA presents with: - Fatigue, muscle weakness (from hypokalemia and acidosis) - Nausea, vomiting (from acidosis) - Polyuria (if concurrent nephrogenic DI from tubulointerstitial disease) - Flank pain or hematuria (if stones or calcifications present)

Diagnosis of Type 1 RTA

Step 1: Establish NAGMA — Calculate anion gap: - AG = Na - (Cl + HCO3) - Normal AG = 8-14 mEq/L - In dRTA, AG should be normal (or low if severe hypoalbuminemia) - If AG is elevated, consider alternative diagnosis

Step 2: Confirm Inability to Acidify Urine — This is the pathognomonic finding: - Random urine pH > 5.5 in the setting of serum pH < 7.35 and HCO3 < 20 is suspicious - More formally: urine pH should be < 5.5 in acidosis; if not, dRTA is likely

Step 3: Calculate Urine Anion Gap (UAG): - UAG = (Na + K) - Cl - Normal UAG is negative (ranges -10 to +2 in healthy people on normal diet) - Positive UAG suggests impaired renal acid excretion (impaired ammoniagenesis or H+ secretion) - In Type 1 RTA: UAG is positive (+5 to +20 typically) - The positive UAG reflects inability to excrete NH4+ (ammonium has a positive charge; when unmeasured anions rise and Cl falls, UAG becomes positive)

Step 4: Check Serum and Urine Electrolytes: - Serum K+ < 3.5 (typically 2.5-3.5) — hypokalemia - Serum Cl high relative to HCO3 (normal anion gap maintained) - Urine Cl low (due to volume contraction and K+ depletion) - Urine K+ may be disproportionately high relative to serum K+ (inappropriate K+ loss)

Step 5: Urine-Blood PCO2 Gradient (Modern functional test): - Normal distal tubule should be able to generate a urine-blood PCO2 difference of > 30 mmHg - Achieved by giving oral NaHCO3 (1-2 grams three times daily for 3 days) to raise serum HCO3 and urine HCO3 load - Collect early morning urine (not first void) - Calculate: (urine PCO2) - (blood PCO2) - Gradient < 30 mmHg in the setting of elevated urine HCO3 indicates impaired distal acidification = dRTA - This test has replaced the older NH4Cl loading test as the gold standard

Step 6: Historical Tests (Less Commonly Performed Now): - NH4Cl loading test: Give 0.1 grams/kg NH4Cl divided doses for 3 days; in healthy people urine pH drops below 5.3, but in dRTA remains > 5.5. Not commonly done now due to safety concerns. - Furosemide-fludrocortisone test: Give furosemide (1 mg/kg IV) + fludrocortisone (0.4 mg orally 10 hours before), which creates a lumen-negative voltage in the collecting duct to drive H+ secretion. If urine pH remains > 5.5, confirms distal defect. Rarely done in practice.

Step 7: Screen for Underlying Etiology: - Autoimmune markers: ANA, anti-Ro/La, RF (Sjögren) - Audiometry (if genetic dRTA suspected, esp. ATP6V1B1) - Renal imaging: ultrasound or low-dose CT (nephrocalcinosis, stones) - Serum calcium, PTH (if hypercalcemia) - Urine citrate level (expect low, typically < 100 mg/day)

Treatment of Type 1 RTA

Goal: Correct acidosis to pH > 7.35 and HCO3 > 20, normalize serum K+, prevent stone formation, and treat underlying etiology if possible.

Alkali Therapy — Cornerstone of Treatment: - Dose: 1-2 mEq/kg/day (divided into 3-4 doses for tolerability) - Much lower dose than Type 2 because there is no bicarbonaturia wasting (the kidney can reabsorb filtered HCO3, the problem is just eliminating acid) - Usual starting dose: 20-40 mEq/day; titrate up as needed - Options: - Sodium bicarbonate (baking soda): 650 mg tablet = 7.7 mEq; take 3 times daily (23 mEq/day) - Sodium citrate (citric acid solution, Shohl solution or commercial preparations): provides both base and citrate - Potassium citrate (preferred): 1080 mg tablet = 10 mEq; addresses both metabolic acidosis AND potassium depletion AND low urine citrate (citrate inhibits stone formation) - Typical dose: 20-30 mEq/day in divided doses (3 tablets twice daily) - Much better than sodium salt in dRTA because hypokalemia is a target and low urine citrate needs correction

Monitoring and Titration: - Check serum electrolytes (Na, K, Cl, HCO3) every 2-4 weeks initially - Target serum K+ 3.5-4.5 mEq/L and HCO3 > 22 - If hypokalemia persists despite potassium citrate, add additional K+ supplementation or potassium chloride - Monitor 24-hour urine citrate (target > 200 mg/day for stone prevention) - Baseline and periodic renal imaging (ultrasound) to monitor nephrocalcinosis progression

Specific Management by Etiology:

• Sjögren syndrome or autoimmune RTA: Alkali therapy is the primary treatment; immunosuppression (corticosteroids, mycophenolate) may be considered if severe systemic disease, but dRTA itself does not reliably respond to immune suppression
• Amphotericin B toxicity: Discontinue if possible; dRTA may improve over weeks to months after cessation, though some damage may be permanent
• Lithium-induced dRTA: Switch to alternative mood stabilizer if possible; dRTA may persist even after stopping lithium
• Genetic dRTA: Lifelong alkali supplementation; prenatal counseling for genetic forms
• Medullary sponge kidney: High-dose alkali + stone prevention measures; watch for CKD progression
• Post-transplant dRTA: Often improves if CNI or other offending drug can be minimized; alkali therapy meanwhile

Complications to Monitor: - Stone formation despite optimal therapy — consider imaging every 1-2 years - Progressive CKD from stone passage or interstitial disease - Bone disease — check bone density, vitamin D status - Hypertension (from high sodium intake if using sodium-based alkali; prefer potassium citrate for this reason)

Pathophysiology

Type 2 RTA results from reduced bicarbonate reabsorption in the proximal tubule, the nephron segment normally responsible for reclaiming approximately 85% of filtered HCO3. The proximal tubule reabsorbs HCO3 via an elegant mechanism: carbonic anhydrase II (CA II) converts luminal HCO3 and secreted H+ into H2CO3, which dissociates to CO2 and H2O. The CO2 freely diffuses into proximal cells where CA II regenerates HCO3 and H+; the H+ is recycled for secretion. Dysfunction at any point in this system reduces HCO3 reabsorption.

The hallmark pathophysiologic feature is a reduced renal threshold for bicarbonate. In healthy people, the serum HCO3 at which the kidney begins to excrete HCO3 in urine (the “threshold”) is around 26 mEq/L. In Type 2 RTA, this threshold is lowered to 14-18 mEq/L (or occasionally lower). This means:

• As serum HCO3 falls from 26 toward 14 mEq/L, the kidney cannot reabsorb all filtered HCO3, so bicarbonaturia develops
• The bicarbinaturia continues until serum HCO3 falls to the new, lower threshold (e.g., 16 mEq/L)
• At the new steady state, all filtered HCO3 is now reabsorbed (because the concentration is at or below threshold), and the urine becomes acid (pH < 5.5)
• The paradox: a patient with Type 2 RTA has NAGMA with an acid urine, not an alkaline urine

This is a crucial diagnostic point: Type 2 RTA can present with urine pH < 5.5, which can be confused with normal renal function. The key is that the urine becomes acid only AFTER serum HCO3 has fallen and the new threshold has been reached. The patient has “sacrificed” a lot of serum HCO3 to achieve this, ending up at a much lower baseline.

Mechanisms of Reduced HCO3 Reabsorption

1. Carbonic Anhydrase Deficiency: - Genetic mutations in CA II or CA IV - Pharmacologic inhibition (acetazolamide, topiramate, dorzolamide) - CA II deficiency is rare but causes Type 2 RTA in isolation

2. H+-ATPase Dysfunction: - Some genetic mutations impair proximal H+ secretion (different from distal defects) - Results in reduced HCO3 reabsorption

3. Impaired Apical Membrane Transport: - SLC4A4 mutations (NBCe1 — sodium-bicarbonate cotransporter) — these mutations reduce the Na-HCO3 co-transporter on the basolateral membrane, which is responsible for exiting HCO3 from the cell after it’s been reabsorbed. Results in Type 2 RTA + ocular manifestations (anterior segment dysgenesis, band keratopathy) - Impaired Na-HCO3 cotransport means HCO3 cannot exit the proximal cell, so less filtered HCO3 is reclaimed

4. Carbonic Anhydrase II Deficiency (Type 3 — Rare): - Autosomal recessive - CA II is critical for both proximal HCO3 reabsorption AND distal H+ secretion, so patients have features of both Type 2 and Type 1 RTA - Also presents with osteopetrosis (dense bones, ironically with fractures due to poor bone quality) and cerebral calcifications - Very rare, mostly in consanguineous families from Middle East/North Africa

Etiologies of Type 2 RTA

Isolated Type 2 RTA — Uncommon: - Genetic: - SLC4A4 mutations (NBCe1) — associated with ocular abnormalities (band keratopathy, anterior segment dysgenesis) - CA II deficiency (Type 3 — with osteopetrosis and CNS calcifications) - Medications: - Acetazolamide (carbonic anhydrase inhibitor — used for glaucoma, altitude sickness, idiopathic intracranial hypertension) - Topiramate (antiepileptic, anticonvulsant; more common cause than acetazolamide in modern practice) - Dorzolamide (topical ophthalmic CA inhibitor, but systemic absorption is possible)

Type 2 RTA as Part of Fanconi Syndrome — Much more common presentation: Fanconi syndrome is generalized proximal tubule dysfunction affecting multiple transport processes. Affected substances include glucose, amino acids, phosphate, urate, and bicarbonate. The HCO3 wasting is just one component of a larger picture of proximal dysfunction.

Most Common Causes of Fanconi + Type 2 RTA:

1. Multiple myeloma — Light chain deposit disease (LCDD) or light chain cast nephropathy
   • Monoclonal light chains (usually kappa) accumulate in proximal tubule cells
   • Direct cytotoxicity causes proximal dysfunction
   • Most common adult cause of acquired Fanconi + Type 2 RTA
   • Classic presentation: older patient with progressive CKD, Fanconi features, and NAGMA
2. Tenofovir (TDF) — Antiretroviral (FDA-approved for HIV and HBV, but increasingly replaced by TAF which is less nephrotoxic)
   • Mitochondrial toxin in proximal tubule cells
   • Causes dose-dependent and cumulative Fanconi syndrome
   • Usually resolves if TDF is discontinued early
   • Note: Newer tenofovir alafenamide (TAF) has much lower rates of renal toxicity
3. Ifosfamide — Alkylating chemotherapy agent
   • Metabolite chloroacetaldehyde damages proximal tubule
   • Fanconi syndrome develops in 20-30% of patients receiving ifosfamide
   • Can be acute (during treatment) or delayed (years after treatment)
   • Often irreversible
4. Heavy Metals:
   • Lead (occupational, old paint, contaminated moonshine)
   • Mercury (occupational, some traditional medicines)
   • Cadmium (occupational, batteries, pigments)
   • Accumulate in proximal cells causing tubulotoxicity
5. Hereditary/Genetic Causes:
   • Cystinosis (most common inherited cause of Fanconi in children)
     • Lysosomal storage disorder; cystine crystals accumulate in proximal tubule
     • Presents in infancy with failure to thrive, rickets, renal failure
     • Now treatable with cysteamine (thiol) therapy, which reduces lysosomal cystine
   • Lowe syndrome (oculocerebrorenal syndrome) — X-linked OCRL mutations
     • Presents with developmental delay, congenital cataracts, renal disease
     • Fanconi syndrome is a component of the renal manifestations
   • Wilson disease — Copper overload; affects proximal tubule (also can cause distal RTA features)
   • Galactosemia — Deficiency of GALT; accumulation of galactose metabolites
   • Hereditary fructose intolerance — Fructose 1-phosphate accumulation in liver and kidney
   • Glycogen storage diseases — Certain types affect renal function
6. Medications (Acquired Fanconi):
   • Outdated tetracycline — Old tetracycline formulations degraded to toxic compounds; newer formulations are safe
   • Cisplatin — Chemotherapy; can cause Fanconi
   • Ifosfamide (mentioned above)
   • Amphotericin B (can cause Fanconi in addition to Type 1 RTA in different patients)
7. Systemic Diseases:
   • Light chain deposition disease (LCDD)
   • Monoclonal immunoglobulin deposition disease (MIDD)
   • Sarcoidosis (granulomatous disease, tubulointerstitial involvement)
   • Amyloidosis (light chain amyloidosis AL)
   • Chronic pyelonephritis (can be part of Fanconi pattern)

Clinical Features of Type 2 RTA

Hypokalemia — Similar to Type 1, but mechanism is different. In Type 2, the proximal reabsorption of filtered Na (coupled to HCO3 reabsorption) is impaired, so more Na is delivered to the distal nephron. The collecting duct takes up this Na via ENaC channels, and in exchange, K+ is secreted. The bicarbinaturia also acts as an impermeant anion, drawing water and Na to the distal tubule, increasing Na delivery and K+ wasting.

Osteomalacia and Rickets — Prominent feature: - Type 2 RTA often occurs as part of Fanconi syndrome with phosphate wasting - Hyperphosphaturia (FEHPO4 > 20%) leads to phosphate depletion - Vitamin D may also be wasted in urine (if Fanconi) or impaired in conversion due to low phosphate - Results in severe bone disease: rickets in children (impaired mineralization), osteomalacia in adults (demineralization) - Patients present with bone pain, muscle weakness, pathologic fractures

Growth Retardation in Children — From acidosis, bone disease, and malnutrition

Absence of Nephrocalcinosis — Unlike Type 1 RTA: - Because at the lower steady-state serum HCO3, the urine can be acidified (distal tubule is intact) - Acidic urine with high citrate (not depleted like in Type 1) prevents stone formation - Therefore, Type 2 RTA patients do NOT develop nephrolithiasis or nephrocalcinosis

Proximal Tubule Dysfunction Features (if Fanconi component): - Glucosuria despite normal serum glucose (negative glucose oxidase test, detected by dipstick) - Generalized aminoaciduria (elevated urinary amino acids) - Uricosuria (high urine uric acid despite normal/low serum uric acid, uric acid dipstick positive) - Phosphaturia (high urine phosphate, typically FEHPO4 > 20%) - Low serum phosphate, low serum urate (wasting) - Elevated alkaline phosphatase (bone disease marker) - May have hypouricemia (paradoxically, despite the “renal” name)

Diagnosis of Type 2 RTA

Step 1: Establish NAGMA — Same as Type 1: - Normal AG - HCO3 typically 14-18 (NADIR)

Step 2: Assess for Fanconi Syndrome (usually present if Type 2): - Glucosuria — dipstick positive glucose in setting of normal serum glucose (< 100 mg/dL fasting) - eFGR < 60, UG/UCr ratio > 0.5 is abnormal (> 1 is definitely abnormal) - Amino aciduria — 24-hour urine amino acids (normal < 200 mg/day; in Fanconi often 500-2000+) - Uricosuria — fractional excretion of urate > 10% (normal < 10%), or serum urate paradoxically low - Phosphaturia — FEHPO4 > 20% (normal < 10%), serum phosphate low (< 2.5), elevated alk phos - Carnitine wasting (some cases)

Step 3: Calculate Urine Anion Gap and Osmolar Gap: - UAG typically positive (impaired ammoniagenesis because proximal tubule is sick) - Urine osmolar gap elevated (reflects unmeasured osmoles including amino acids, glucose)

Step 4: Fractional Excretion of HCO3 (FEHCO3) — The definitive test: - Measure after giving oral sodium bicarbonate loading (1-2 grams three times daily for 3 days) to raise serum HCO3 above the patient’s apparent threshold - FEHCO3 = (Urine HCO3 × serum Cr) / (serum HCO3 × urine Cr) × 100% - Normal FEHCO3 at serum HCO3 > 25: < 5% (kidney reabsorbs almost all filtered HCO3) - In Type 2 RTA: FEHCO3 > 15% (hallmark finding — > 15% after HCO3 loading indicates proximal leak of HCO3) - In Type 1 RTA: FEHCO3 remains < 5% (HCO3 is reabsorbed, but cannot be excreted as acid)

Step 5: Serum and Urine Electrolytes: - Hypokalemia (K+ 2.5-3.5) - Serum phosphate low (< 2.5 if Fanconi) - 24-hour urine potassium elevated (indicating urinary K+ wasting) - If Fanconi: check urine amino acids, urate, glucose

Step 6: Screen for Etiology: - Medications: review history for acetazolamide, topiramate, tenofovir, ifosfamide, outdated tetracycline - Multiple myeloma screening: serum/urine protein electrophoresis, immunoglobulin levels, serum free light chains, bone marrow biopsy - Heavy metals: occupational history, 24-hour urine heavy metals if exposure suspected - Genetic causes: family history, age of onset - Cystinosis: slit-lamp exam (cystine crystals in cornea), plasma amino acids, urine cystine - Wilson disease: serum ceruloplasmin, 24-hour urine copper, slit-lamp for Kayser-Fleischer rings - Renal imaging: usually normal in isolated Type 2; medullary echogenicity may be seen in cystinosis

Treatment of Type 2 RTA

Goal: Correct acidosis toward normal serum HCO3 (> 22), normalize K+, prevent bone disease progression, treat underlying cause.

Alkali Therapy — High-Dose Requirement: - Dose: 10-15 mEq/kg/day (much higher than Type 1) - Reason: significant bicarbinaturia continues while serum HCO3 is being raised; bicarbonate is “wasted” in urine, so more must be given - Example: 60 kg patient may need 600-900 mEq/day divided into multiple doses throughout the day - This is impractical with oral sodium bicarbonate alone (would require 80+ tablets daily) - Options: - Potassium citrate — preferred if hypokalemia present - Sodium citrate (Shohl solution or others) - Combine agents as needed for compliance - Titrate to target HCO3 > 22 and serum K+ > 3.5

Thiazide Diuretics — Adjunctive Therapy: - Mechanism: thiazides cause mild volume depletion, which reflexively increases proximal tubule Na reabsorption - Increased proximal Na reabsorption is coupled to HCO3 reabsorption, so more HCO3 is reclaimed - This reduces the amount of alkali needed to maintain serum HCO3 - Dose: hydrochlorothiazide 25 mg daily - Caution: thiazides cause hypokalemia themselves, so K+ supplementation must be carefully adjusted - Not all Type 2 RTA patients need thiazides; use if alkali doses become unmanageable

Phosphate and Vitamin D Supplementation (if Fanconi): - Phosphate supplementation: sodium or potassium phosphate 1-3 grams daily in divided doses (caution: phosphate is unpalatable) - Vitamin D: cholecalciferol (vitamin D3) 2,000-4,000 IU daily, or calcitriol (1,25-dihydroxyvitamin D, active form) 0.5-1 mcg twice daily if severe hypophosphatemia - Monitor serum phosphate, calcium, magnesium (can become depleted with vigorous supplementation) - Bone imaging and metabolic bone disease assessment

Treatment of Underlying Cause: - Tenofovir-induced: switch to TAF (tenofovir alafenamide) if possible; Fanconi syndrome often improves with discontinuation - Acetazolamide/topiramate: switch to alternative medication if possible (acetazolamide can be stopped, topiramate may be harder if seizure control needed) - Multiple myeloma: treat with chemotherapy (bortezomib, lenalidomide, others); Fanconi may improve with disease remission - Cystinosis: cysteamine (thiol therapy) reduces lysosomal cystine and slows progression - Heavy metal exposure: remove from exposure source - Wilson disease: copper chelation (penicillamine or zinc)

Monitoring: - Serum electrolytes, HCO3, phosphate, calcium every 2-4 weeks initially - 24-hour urine electrolytes including amino acids and phosphate - Bone density screening (DEXA scan); assess for rickets/osteomalacia - Screen for CKD progression (GFR monitoring)

Clinical Features and Diagnosis

Systemic manifestations beyond RTA: - Osteopetrosis (marble bone disease) — paradoxically dense but weak bones; osteoclasts cannot resorb bone (osteoclasts rely on CA II to generate the acidic microenvironment needed for bone resorption); patients have increased fracture risk despite dense appearance - Cerebral calcifications — subcortical white matter and basal ganglia calcifications visible on brain imaging; neurologic manifestations variable (developmental delay, seizures, or asymptomatic) - RTA features — both distal (inability to acidify, hypokalemia) and proximal (bicarbinaturia when HCO3 is raised, some Fanconi features possible)

Inheritance and Epidemiology

• Autosomal recessive
• Extremely rare; mostly reported in consanguineous families from Middle East (Saudi Arabia, Tunisia, Egypt) and North Africa
• No cases routinely seen in Western medical practice; mostly academic interest

Management

• Lifelong alkali therapy (similar to Type 1 RTA, but may need higher doses due to proximal component)
• Supportive care for bone disease
• No specific cure; management is supportive

Pathophysiology

Type 4 RTA results from impaired distal nephron potassium and hydrogen ion secretion. Unlike Type 1 (where the problem is H+ secretion only) or Type 2 (where the problem is HCO3 reabsorption), Type 4 results from dysfunction in the renin-angiotensin-aldosterone system (RAAS) or in the principal cells of the collecting duct.

Primary Mechanisms:

1. Aldosterone Deficiency (Hyporeninemic Hypoaldosteronism): - Renin production is suppressed (usually from tubulointerstitial disease), leading to low aldosterone - Without aldosterone, principal cells of the collecting duct cannot activate epithelial sodium channels (ENaC) to reabsorb Na and secrete K+ - Loss of lumen-negative transepithelial voltage (normally generated by Na reabsorption) - Without this negative voltage, K+ and H+ secretion are impaired

2. Aldosterone Resistance (Renal Insensitivity): - Aldosterone levels are normal or elevated, but the kidney cannot respond - Either from receptor mutations (genetic), medications blocking ENaC or aldosterone receptor, or tubulointerstitial disease damaging the collecting duct - Result is functionally similar to aldosterone deficiency: inability to secrete K+ and H+

3. The Hyperkalemia Perpetuates Acidosis — A critical mechanism: - Hyperkalemia directly suppresses ammoniagenesis in the proximal tubule - Ammonia synthesis (glutaminase) is inhibited by high serum K+ - Lower ammonia production means less NH4+ available in the lumen for distal trapping and urinary excretion - NH4+ is the primary urinary buffer for acid; without it, acid cannot be excreted effectively - This creates a vicious cycle: low aldosterone → high K+ → low NH4+ production → acidosis worsens → more K+ retention → more suppression of NH4+

Etiologies of Type 4 RTA

Type 4 RTA has more etiologies than other types, reflecting the multiple ways the RAAS and collecting duct can be disrupted. These are organized into two categories:

Category A: Aldosterone Deficiency (Hyporeninemic Hypoaldosteronism)

These conditions suppress renin production, leading to low aldosterone despite ongoing physiologic stimulus for its release:

1. Diabetic Nephropathy (#1 cause of Type 4 RTA)
   • Diabetes with CKD (GFR 30-60) develops hyporeninemic hypoaldosteronism
   • Mechanism: tubulointerstitial fibrosis suppresses renin-producing juxtaglomerular cells
   • Presents with mild-moderate CKD, hyperkalemia, and NAGMA
   • Often worsened by ACEi/ARB therapy (see below)
   • Prevalence: 5-10% of diabetic CKD patients
2. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
   • Chronic use suppresses renin release via prostaglandin inhibition
   • NSAIDs are potent suppressors of renin
   • Risk factors for Type 4 RTA: diabetics, CKD, elderly, dehydration, concurrent ACEi/ARB
   • Can develop acutely or insidiously with chronic use
3. Calcineurin Inhibitors (CNI)
   • Cyclosporine and tacrolimus commonly cause hyperkalemic RTA post-transplant
   • Mechanism: both tubulointerstitial toxicity (reduces renin) + direct renal vasoconstriction
   • Very common in cardiac and renal transplant recipients
   • May develop months to years after transplantation
4. Heparin (Unfractionated and LMWH)
   • Suppresses aldosterone synthesis directly at the adrenal cortex
   • Can develop acutely (within days of heparin initiation)
   • Risk factors: high-dose heparin (> 15,000 U/day), underlying renal disease, diabetes
   • Resolves within days of stopping heparin
5. Primary Adrenal Insufficiency (Addison Disease)
   • Autoimmune destruction or other etiology of adrenal glands
   • Results in combined cortisol AND aldosterone deficiency
   • Presents with hypotension, hyponatremia, hyperkalemia, NAGMA
   • Distinguished from other causes by low cortisol (ACTH stimulation test)
6. Congenital Adrenal Hyperplasia (CAH)
   • 21-hydroxylase deficiency (most common, ~90% of CAH)
   • Impaired cortisol synthesis → blocks aldosterone pathway → low aldosterone
   • Usually presents in infancy/childhood with salt-wasting crisis
   • Can present subtly in adults with hyperkalemia + NAGMA
7. ACE Inhibitors and Angiotensin II Receptor Blockers (ACEi/ARB)
   • Reduce angiotensin II formation (ACEi) or block AT1 receptor (ARB)
   • Without angiotensin II, aldosterone synthesis is suppressed
   • NOT the primary mechanism of hyperkalemia from ACEi/ARB (they also reduce GFR and block distal Na delivery), but a contributing factor
   • Risk factors: diabetics, CKD, combination therapy (ACEi + ARB + spironolactone)
   • Clinical pearl: if hyperkalemia develops after starting ACEi/ARB, either dose reduction or addition of loop diuretic can help
8. HIV-Associated Adrenalitis
   • HIV and/or opportunistic infections (CMV, tuberculosis, mycobacteria) directly damage adrenal glands
   • Results in cortisol and aldosterone deficiency
   • More common in advanced AIDS (CD4 < 50)

Category B: Aldosterone Resistance (Normal/High Aldosterone, But Kidney Cannot Respond)

These conditions have aldosterone levels that are normal or appropriately elevated, but the kidney’s collecting duct is either genetically unable to respond or blocked by medication.

1. Medications Blocking Mineralocorticoid Receptor (MR Antagonists)
   • Spironolactone (most common — used for HTN, HF, ascites)
   • Eplerenone (selective MR antagonist, used for HTN, post-MI HF)
   • Mechanism: competitive inhibition of aldosterone at the MR
   • Hyperkalemia develops in 10-15% of patients on spironolactone, especially those with CKD
2. Medications Blocking Epithelial Sodium Channels (ENaC):
   • Trimethoprim (antibiotic) — blocks ENaC acutely; hyperkalemia can develop within days
     • Risk factors: CKD, dehydration, elderly
     • Very commonly missed; often attributed to other causes
   • Pentamidine (antimicrobial for PCP prophylaxis and treatment) — similar mechanism to trimethoprim
   • Amiloride and Triamterene (potassium-sparing diuretics) — intentionally block ENaC; hyperkalemia is expected side effect
3. Pseudohypoaldosteronism Type 1 (PHA1)
   • Rare genetic condition with two forms:
     • Autosomal recessive (systemic/severe): mutations in SCNN1B or SCNN1G genes (encoding ENaC subunits); presents in infancy with severe salt wasting, hyperkalemia, NAGMA, and elevated aldosterone
     • Autosomal dominant (renal/mild): mutations in the MR gene itself; variable severity, some cases asymptomatic with incidental lab abnormality
   • The kidney cannot respond to aldosterone because the receptor or downstream sodium channel is dysfunctional
   • Serum aldosterone is HIGH (appropriately trying to compensate) but ineffective
4. Pseudohypoaldosteronism Type 2 (PHA2 / Familial Hyperkalemic Hypertension, FHHt)
   • NOT a true aldosterone resistance; complex tubulointerstitial mechanism
   • Mutations in WNK1 or WNK4 kinases
   • Results in chloride shunting in the distal convoluted tubule (NaCl reabsorption bypasses normal K+ secretion pathway)
   • Patients present with hyperkalemia, HTN (distinguishes from Type 4 RTA), and hyperchloremia
   • Very rare, mostly of academic interest
5. Obstructive Uropathy
   • Chronic (but not acute) obstruction can lead to Type 4 RTA
   • Mechanism: tubulointerstitial damage from back-pressure
   • Improves after relief of obstruction
6. Sickle Cell Disease
   • Multiple mechanisms: tubulointerstitial scarring from infarction, distal RTA features from collecting duct damage
   • Hyperkalemia develops in advanced CKD
7. SLE with Tubulointerstitial Nephritis
   • Lupus tubulointerstitial nephritis can damage the distal tubule/collecting duct
   • Results in Type 4 RTA features
8. Amyloidosis (Light Chain)
   • AL (light chain) amyloidosis deposits in kidney tissue
   • Can cause Type 4 RTA if collecting duct is involved
9. Chronic Kidney Transplant Rejection
   • Can develop Type 4 RTA over time

Clinical Features and Presentation

Hyperkalemia — The most important distinguishing feature (K+ typically 5.5-7 mEq/L): - Often asymptomatic at mild levels (5.5-6 mEq/L) - Symptoms at higher levels: muscle weakness, palpitations, EKG changes - Can cause sudden cardiac dysrhythmias or cardiac arrest if severe (K+ > 7)

Mild Metabolic Acidosis — Less severe than Types 1 and 2: - Serum HCO3 typically 15-20 mEq/L (compared to 10-14 in Type 1) - Serum pH 7.25-7.35 - Less symptomatic (fatigue, anorexia, but not severe dyspnea or altered mental status usually)

Urine pH — Usually < 5.5: - The collecting duct is intact and capable of acidification - The problem is not H+ secretion per se, but the voltage gradient driving it is reduced - Total acid excretion is low (low NH4+ due to suppression by hyperkalemia and hypoaldosteronism)

Associated Features Depend on Etiology: - If diabetic: signs of diabetes (polyuria, retinopathy, neuropathy) - If post-transplant: clinical signs of transplant function (urine output, creatinine, proteinuria) - If adrenal insufficiency: hypotension, hyponatremia, hypoglycemia, pigmentation changes - If on spironolactone: edema, ascites (conditions it was prescribed to treat)

Diagnosis of Type 4 RTA

Step 1: Recognize the Triad: - NAGMA (normal AG) - Hyperkalemia (K+ > 5.5) - Mild acidosis (HCO3 15-20)

Step 2: Calculate Urine Anion Gap: - UAG may be positive or negative (less reliably positive than Types 1/2) - Reason: some K+ is excreted (creating a positive charge), offsetting the positive anion gap - Presence of positive UAG with hyperkalemia strongly suggests impaired distal acid excretion

Step 3: Check Transtubular Potassium Gradient (TTKG): - TTKG = (Urine K × Serum Cr) / (Serum K × Urine Cr) - Normal TTKG at high serum K+ should be > 8-10 (kidney should respond to hyperkalemia by increasing K+ secretion) - In Type 4 RTA: TTKG < 6-8 despite high serum K+ (indicates inappropriately low renal K+ excretion) - Caveat: TTKG has significant limitations and is less reliable than direct measurement; should not be used in isolation

Step 4: Differentiate Aldosterone Deficiency from Aldosterone Resistance: This is crucial to determine treatment:

Check serum aldosterone and plasma renin activity (PRA):

Step 5: Look for Clues to Etiology: - Medication review: spironolactone, ACEi/ARB, NSAIDs, trimethoprim, heparin, cyclosporine, tacrolimus - Diabetes history: if diabetic + CKD + Type 4 RTA, likely diabetic hyporeninemic hypoaldosteronism - Transplant status: if post-renal or heart transplant, CNI-induced - Adrenal function: if hypotensive or hyponatremic, check cortisol - Urine electrolytes: measure 24-hour urine Na and K to assess Na avidity

Treatment of Type 4 RTA

Treatment differs based on whether the problem is aldosterone deficiency or aldosterone resistance. Empiric therapy before the distinction is made should focus on dietary measures and diuretics.

A. If Aldosterone Deficiency (Low Renin, Low Aldosterone):

Fludrocortisone — Synthetic mineralocorticoid (aldosterone analog): - Dose: 0.1-0.2 mg daily (often start 0.1 mg, titrate up) - Mechanism: activates MR in collecting duct → opens ENaC → Na reabsorption → K+ secretion - Monitoring: check serum K+ at 1-2 weeks; target K+ 4-5 mEq/L - Side effects: hypertension (common), edema, hypokalemia if overdosed (titrate carefully), hypernatremia - Caution: avoid in HF, ascites (volume expansion), HTN already present - Adjuncts: may combine with loop diuretic (furosemide) to increase K+ excretion if fludrocortisone alone insufficient

Combination Therapy — Fludrocortisone + Loop Diuretic: - Furosemide 40-80 mg daily - Loop diuretic increases distal Na delivery → increases K+ secretion - Must monitor for hypokalemia, hyponatremia, and GFR (diuretics worsen CKD)

B. If Aldosterone Resistance (High Renin, High Aldosterone, or Normal Aldosterone but Receptor/Channel Block):

Fludrocortisone will NOT work (kidney cannot respond to aldosterone). Instead:

Loop Diuretics: - Furosemide 40-160 mg daily in divided doses - Mechanism: increase renal Na excretion and distal Na delivery → increased K+ secretion (volume contraction effect) - Titrate to urine K+ 40-60 mEq/day (goal is to reduce hyperkalemia) - Monitor: electrolytes, GFR, orthostasis

Dietary Potassium Restriction: - Target < 2 grams (50 mEq) daily - Avoid high-K foods: bananas, oranges, tomatoes, potatoes, nuts, chocolate, salt substitutes - Often the most important single intervention - Patient education is critical for compliance

Sodium Bicarbonate (Alkali Therapy): - For metabolic acidosis component - Dose: 1-2 mEq/kg/day (1-2 tablets three times daily) - May improve hyperkalemia slightly (Na load → dilutes K+, bicarbonate → shifts K+ intracellularly) - Less critical than K+ reduction, but important for pH correction

Stop Offending Medications (if possible): - Spironolactone, amiloride, triamterene — switch to alternative diuretic if needed for HTN/volume management - Trimethoprim — use alternative antibiotic if possible - NSAIDs — avoid or minimize; switch to acetaminophen or topical NSAIDs - ACEi/ARB — can continue if absolutely necessary (e.g., HF, proteinuria), but dose-reduce; may need to accept mild hyperkalemia if drug essential - Pentamidine — switch to alternative if possible

Potassium Binders (Newer Agents): - Patiromer (Veltassa): cation-exchange polymer; binds K+ in colon, reducing serum K+ - Dose: 8.4 grams daily, taken 3+ hours apart from other medications - Slow onset (days to weeks), modest effect (reduces K+ by ~0.5-1 mEq/L) - May cause hypomagnesemia, constipation - Useful for refractory hyperkalemia - Sodium zirconium cyclosilicate (SZC, Lokelma): microporous inorganic compound; binds K+ in GI tract - Dose: 10 grams three times daily (for 3 days loading), then 10 grams daily maintenance - Faster onset than patiromer (hours to days) - Side effects: hyponatremia (sodium-based binder), edema, hypertension - Useful for acute or chronic management

Acute Hyperkalemia Management (if K+ > 6.5 or EKG changes): - This requires hospital-level interventions; not discussed in detail here - Agents: calcium gluconate (membrane stabilization), insulin + dextrose (intracellular K+ shift), beta-2 agonists (albuterol), diuretics, hemodialysis if severe

Type 4 RTA in Special Populations

Diabetic CKD Patients: - Type 4 RTA very common (5-10% of diabetics with CKD) - Presents insidiously; often detected on routine labs - Challenge: diabetics often NEED ACEi/ARB for renal protection, but these worsen hyperkalemia - Solution: use spironolactone cautiously (benefits HF, but worsens RTA), add loop diuretic, dietary K+ restriction, or minimize ACEi/ARB if hyperkalemia severe

Post-Transplant Patients: - CNI-induced Type 4 RTA very common (10-30% of transplant recipients depending on CNI dose and duration) - May develop months to years after transplant - Management: minimize CNI dose if possible, add loop diuretic, dietary K+ restriction, avoid spironolactone

Elderly Patients: - Type 4 RTA increasingly common with age (>65 years) - Often on multiple medications contributing to hyperkalemia (ACEi, NSAID, spironolactone, trimethoprim) - Polypharmacy complicates management; medication review critical - Greater risk of hyperkalemia complications (arrhythmia risk)

RTA in Pregnancy

Physiologic Changes in Pregnancy: - Pregnancy induces a mild respiratory alkalosis (PCO2 decreases to 28-32 mmHg) - This is compensatory for metabolic acidosis induced by fetal lactate production - Normal serum HCO3 in pregnancy is 18-21 (lower than non-pregnant)

Effects on Pre-existing RTA: - Type 1 RTA: May worsen during pregnancy due to increased acid load and volume changes; requires increased alkali therapy - Type 2 RTA: Fanconi-related RTAs (e.g., cystinosis) may worsen due to physiologic volume changes; fetal complications risk if maternal disease severe - Type 4 RTA: Pregnancy-related hemodynamic changes may exacerbate hyperkalemia; careful medication review needed (avoid ACEi/ARB, NSAIDs, spironolactone)

Management in Pregnancy: - Continue alkali therapy; may need dose adjustment (increased requirements in Types 1-2) - More frequent K+ monitoring in Type 4 - Avoid NSAIDs, ACEi/ARB, spironolactone during pregnancy if possible - Coordinate care with obstetrics and nephrology

RTA in Pediatric Patients

Cystinosis — Most common cause of Type 2 RTA with Fanconi syndrome in children: - Autosomal recessive storage disorder - Cystine accumulation in lysosomes of proximal tubule cells - Presents in infancy (weeks to months) with: failure to thrive, rickets, renal dysfunction, Fanconi - Diagnosis: elevated urine cystine, cystine crystals on slit-lamp - Treatment: cysteamine (thiol therapy) — reduces lysosomal cystine, slows CKD progression - Without treatment, ESRD by age 10; with treatment, progression delayed

Genetic Type 1 RTA with Deafness (ATP6V1B1 mutations): - Usually detected by newborn hearing screening - Early diagnosis and alkali therapy can prevent kidney stone formation and preserve renal function

Growth and Development: - Chronic RTA impairs linear growth; alkali therapy improves growth velocity - Bone disease (rickets) is prominent in Type 2 RTA; vitamin D and phosphate supplementation critical - Neurologic development may be affected in Type 3 RTA (from carbonic anhydrase II deficiency and cerebral calcifications)

RTA in CKD and Distinguishing from CKD Metabolic Acidosis

Challenge: Patients with GFR 30-60 can have either Type 4 RTA or early CKD metabolic acidosis; the two can coexist.

Key distinguishing feature: In Type 4 RTA, if you can lower serum K+ aggressively (dietary restriction, loop diuretic, K+ binder), the acidosis often improves. In CKD acidosis, the acidosis persists even with K+ control (because phosphate retention and progressive GFR loss drive acidosis).